PMID- 8104811
OWN - NLM
STAT- MEDLINE
DCOM- 19931109
LR  - 20190624
IS  - 0014-2999 (Print)
IS  - 0014-2999 (Linking)
VI  - 238
IP  - 2-3
DP  - 1993 Jul 20
TI  - 5-HT2 receptor-mediated potentiation of dopamine synthesis and central 
      serotonergic deficits.
PG  - 291-6
AB  - The hypothesis was tested that serotonin (5-HT) modulates 
      3,4-methylenedioxymethamphetamine (MDMA)-induced increase in dopamine synthesis. 
      Rats were treated with the selective 5-HT2 receptor agonist 
      (R)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (R-DOI), the selective 
      serotonin releasing agent 5-methoxy-6-methyl-2-aminoindan (MMAI), amphetamine, 
      MDMA, or a combination of amphetamine and R-DOI or MMAI, followed by the 
      L-dihydroxyphenylalanine (DOPA) decarboxylase inhibitor 3-hydroxybenzylhydrazine 
      (NSD-1015). Rats were killed 45 min after the first injection and striatal DOPA 
      was determined. R-DOI, MMAI, or amphetamine alone did not increase DOPA 
      accumulation. However, combination of amphetamine with either MMAI or R-DOI 
      significantly increased DOPA accumulation. Multiple doses of the R-DOI and 
      amphetamine combination did not decrease [3H]paroxetine binding sites at one week 
      after killing. The results indicate that the dopamine synthesis increasing effect 
      of MDMA depends both on 5-HT2 receptor stimulation and dopamine efflux.
FAU - Huang, X
AU  - Huang X
AD  - Department of Pharmacology and Toxicology, Purdue University, School of Pharmacy 
      and Pharmacal Sciences, West Lafayette, IN 47907.
FAU - Nichols, D E
AU  - Nichols DE
LA  - eng
GR  - DA04758/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Amphetamines)
RN  - 0 (Aromatic Amino Acid Decarboxylase Inhibitors)
RN  - 0 (Hydrazines)
RN  - 0 (Indans)
RN  - 0 (Receptors, Serotonin)
RN  - 0 (Serotonin Antagonists)
RN  - 0 (Serotonin Receptor Agonists)
RN  - 132980-16-6 (5-methoxy-6-methyl-2-aminoindan)
RN  - 333DO1RDJY (Serotonin)
RN  - 4764-17-4 (3,4-Methylenedioxyamphetamine)
RN  - 63-84-3 (Dihydroxyphenylalanine)
RN  - A27K5Q85R2 (3-hydroxybenzylhydrazine)
RN  - CK833KGX7E (Amphetamine)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
RN  - OOM10GW9UE (4-iodo-2,5-dimethoxyphenylisopropylamine)
RN  - VTD58H1Z2X (Dopamine)
SB  - IM
MH  - 3,4-Methylenedioxyamphetamine/*analogs & derivatives/pharmacology
MH  - Amphetamine/pharmacology
MH  - Amphetamines/pharmacology
MH  - Animals
MH  - Aromatic Amino Acid Decarboxylase Inhibitors
MH  - Corpus Striatum/*drug effects/metabolism
MH  - Dihydroxyphenylalanine/*metabolism
MH  - Dopamine/*biosynthesis
MH  - Hippocampus/*drug effects/metabolism
MH  - Hydrazines/pharmacology
MH  - Indans/pharmacology
MH  - Male
MH  - N-Methyl-3,4-methylenedioxyamphetamine
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Receptors, Serotonin/drug effects/*physiology
MH  - Serotonin/*physiology
MH  - Serotonin Antagonists/pharmacology
MH  - Serotonin Receptor Agonists/pharmacology
EDAT- 1993/07/20 00:00
MHDA- 1993/07/20 00:01
CRDT- 1993/07/20 00:00
PHST- 1993/07/20 00:00 [pubmed]
PHST- 1993/07/20 00:01 [medline]
PHST- 1993/07/20 00:00 [entrez]
AID - 0014-2999(93)90859-G [pii]
AID - 10.1016/0014-2999(93)90859-g [doi]
PST - ppublish
SO  - Eur J Pharmacol. 1993 Jul 20;238(2-3):291-6. doi: 10.1016/0014-2999(93)90859-g.